PharmaNest to Present Seven Digital Pathology and AI Communications at EASL 2024

PharmaNest, a leader in high-resolution quantitative Digital Pathology and Artificial Intelligence, will present seven abstracts at the International Liver Congress - EASL in Milan from June 5-8, 2024. These presentations will focus on the performance and clinical utility of the FibroNest Ph-FCS biomarker for Metabolic Associated Steatohepatitis (MASH).

FibroNest is a high-resolution, single-fiber digital pathology platform used to assess fibrosis and inflammation severity in MASH. The presentations will cover analytical validation, accuracy, reproducibility, repeatability, and intra-liver variability. Additionally, they will demonstrate the biomarker's sensitivity in detecting fibrosis changes post-bariatric surgery.

Oral and poster presentations will highlight the utility of FibroNest in screening anti-fibrotic compounds and evaluating complex fibrosis phenotypes in the extracellular matrix. This includes understanding the relationship to intrahepatic cholangiocarcinoma.

CEO Mathieu Petitjean stated that the automated quantification provides a robust method to generate digital biomarkers, offering a scalable means to account for intervention efficacy and predict liver-related clinical events throughout the drug discovery process.

The presentations cover a range of topics, including AI-assisted pathology, efficacy insights on antifibrotic compounds, and performance evaluations of cellular profiling techniques and AI digital pathology methods.